DARE Stock Analysis: Buy, Sell, or Hold?
DARE - Dare Bioscience, Inc. Common Stock
$2.09
-0.02 (-0.95%)
▼
5d:
+4.5%
30d:
-2.34%
90d:
+10.0%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When DARE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: DARE shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: DARE shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: DARE is currently trading at $2.09, which is considered fair relative to its 30-day fair value range of $1.97 to $2.21. From a valuation perspective, the stock is trading at a discount (Forward PE: -4.1) compared to its historical average (3.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DARE is in a uptrend. Immediate support is located at $1.85, while resistance sits at $2.50.
Market Sentiment: DARE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.67 (+362.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DARE is in a uptrend. Immediate support is located at $1.85, while resistance sits at $2.50.
Market Sentiment: DARE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.67 (+362.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.97 -
$2.21
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
88.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 362.5% below Wall St target ($9.67)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$1.97 -
$2.21
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.85
Resistance Level
$2.50
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.10
Wall Street Target
$9.67
(+362.5%)
Revenue Growth (YoY)
499.6%
PE vs Historical
-4.1 vs 3.6
CHEAP
Share & Embed Analysis
Last updated: July 02, 2026 10:38 PM ET
Data refreshes hourly during market hours. Next update: 11:38 PM
Data refreshes hourly during market hours. Next update: 11:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DARE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 51 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 55 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 64 BUY |
